OrbusNeich Medical Group Holdings (HKSE:06929) Risk Assessment

View and export this data going back to 2022. Start your Free Trial

What is OrbusNeich Medical Group Holdings Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of OrbusNeich Medical Group Holdings is: No Data: Cannot be evaluated.

Competitive Comparison of OrbusNeich Medical Group Holdings's Risk Assessment

For the Medical Instruments & Supplies subindustry, OrbusNeich Medical Group Holdings's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OrbusNeich Medical Group Holdings's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OrbusNeich Medical Group Holdings's Risk Assessment distribution charts can be found below:

* The bar in red indicates where OrbusNeich Medical Group Holdings's Risk Assessment falls into.

Save Embed

;

Save Embed

;

OrbusNeich Medical Group Holdings (HKSE:06929) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

OrbusNeich Medical Group Holdings Risk Assessment Related Terms

Thank you for viewing the detailed overview of OrbusNeich Medical Group Holdings's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

OrbusNeich Medical Group Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OrbusNeich Medical Group Holdings Ltd (HKSE:06929) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

Q8T:Germany

Address

3rd Floor, Building 20E, Units 303 and 305, Hong Kong Science Park, Shatin New Town, Hong Kong, HKG

Website

https://www.orbusneich.com

OrbusNeich Medical Group Holdings Ltd is a China-based medical device maker of endovascular interventional instruments with majority reach. It launched its first research base in 2001 and was listed on the Hong Kong Exchange in 2022. As of 2023, OrbusNeich's majority revenue segment by geography is Japan with 24.7% of total revenue followed by Europe, the Middle East, and Africa, with 23.6% of total revenue. The Asia-Pacific region and the United States make up the balance. Its product segment is coronary interventional medical devices, such as scoring balloons, non-compliant balloons, or stents, together representing 82.7% of its total revenue.

Executives

Harmony Tree Limited	2101 Beneficial owner
Shenzhen Capital Group Co., Ltd.	2201 Interest of corporation controlled by you
Suzhou Red Earth Yeju Investment Ltd.	2101 Beneficial owner
Chien David	2201 Interest of corporation controlled by you
Lau Kwai Ching Denise	2201 Interest of corporation controlled by you
Shen Chuang Tou Zhi Zao Ye Zhuan Xing Sheng Ji Xin Cai Liao Ji Jin You Xian He Huo	2201 Interest of corporation controlled by you
Shen Chuang Tou Hong Tu Si Mu Gu Quan Tou Zi Ji Jin Guan Li Shen Zhen You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Hong Tu Ye Ju Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you

OrbusNeich Medical Group Holdings Headlines

No Headlines